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Abstract 
 Recent advances in antiviral therapy have improved outcomes in HIV-positive 
individuals co-infected with hepatitis B and C virus (HBV/ HCV).  Our aim was to 
assess prevalence and predictors of chronic liver disease (CLD) due to the metabolic 
syndrome (MS), alcohol and antiretrovirals (ARVs) use in HIV monoinfected 
individuals. This was a retrospective cohort study (2005-2012). HIV-positive patients 
with negative HBV/HCV serology and at least two elevated alanine aminotransferase 
(ALT) levels six months apart were included. Data are presented as mean ±SD or 
percentage. Despite negative viral serology, 27% (1047/3872) of HIV positive 
individuals had persistently elevated ALT. Only 243 (23.2%) were investigated (by 
imaging in the majority, only 58 undergoing liver biopsy/transient elastography). CLD 
was identified in 66.2%, this being clinically significant in 1 in 4 individuals. Potential 
CLD risk factors were alcohol (44.2%), hepatotoxic ARVs (74.1%) and MS risk factors 
(68%) with 68.7% having >1 risk factor. On multivariate logistic regression analysis 
serum triglyceride (OR 1.482, 95% CI 1.053-2.086, p=0.024) was the only independent 
predictor of CLD. Overall, 4.3% were referred to Hepatology services. In conclusion 
less than 6% of HIV monoinfected individuals with persistently elevated ALT undergo 
objective assessment of hepatic fibrosis. Despite non-stringent criteria, some degree of 
non-viral CLD is identified in approximately two-thirds of those investigated, risk 
factors being synonymous with those for the MS. This increasing yet under-recognised 
non-viral CLD burden warrants timely recognition to prevent long-term morbidity and 
mortality. 
Key words: chronic liver disease, alcohol use, metabolic syndrome, antiretroviral 
therapy, fatty liver. 
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Introduction 
In HIV positive individuals liver disease [mostly due to hepatitis B and C virus (HBV 
and HCV)] is the third most common cause of mortality after AIDS related illness and 
non-AIDS non-viral malignancy (Morlat et al.; 2000). However, the discovery of direct 
acting antiviral (DAA) drugs has resulted in a paradigm shift in the management of 
HCV infection (Aghemo & De Francesco, 2013). The future liver disease burden in 
HIV-positive individuals is likely to be due to alcohol related liver disease (ARLD), 
non-alcoholic fatty liver disease (NAFLD) and/or antiretrovirals (ARV) related. Our 
aim therefore was to assess prevalence, aetiology, and predictors of non-viral related 
chronic liver disease (CLD) in a cohort with HIV mono infection. 
Methods 
This retrospective longitudinal cohort study was  conducted at a  teaching hospital in 
South East England from 2005-2012. The electronic HIV database was screened to 
identify HBV and HCV negative individuals with at least two alanine aminotransferase 
(ALT) levels>upper limit of normal (ULN) six months apart who had been investigated 
with one or more of the following: imaging (ultrasonography (USG), computed 
tomography (CT) and magnetic resonance imaging (MRI), Transient elastography (TE) 
and/or a liver biopsy. The interval between persistently elevated ALT and further 
investigations was not specifically recorded though was less than 12 months in most 
cases.  Those with a positive HBV and HCV serology and or incomplete/ unavailable 
medical records were excluded 
Study definitions 
4 
 
CLD: presence of one or more of the following:> F1 metavir fibrosis on liver biopsy 
(Bedossa &Poynard, 1996) and or liver stiffness measurement (LSM) > F1 (metavir) on 
TE; imaging showing any one of the following: fatty liver, heterogenous or irregular 
liver (Allan, Thoirs & Phillips, 2010);  
Clinically significant liver disease as defined as: presence of one or more of the 
following:  ≥F2 fibrosis (metavir) on liver biopsy and or LSM > F2 (metavir) on TE; 
moderate to severe hepatic steatosis on liver biopsy; portal hypertension (cirrhotic or 
non-cirrhotic); hepatic decompensation; and liver related mortality  
Medical records of individuals fulfilling study criteria were retrospectively reviewed 
and data collected. Individuals were classified into three groups according to potential 
CLD risk factors (could be classified into more than one category). 
Alcohol-related: ≥ 21units alcohol per week for men and ≥ 14 units alcohol per week 
for women. 
Metabolic syndrome (MS) related: one or more risk factor for the MS [(dyslipidaemia 
defined as total cholesterol >5mmol/L, HDL <1.0mmol/L, LDL >3.mmol/L, 
triglycerides >2.0mmol/L); BMI > 30; diabetes mellitus (DM)/ impaired glucose 
tolerance (defined as a fasting plasma glucose <7 mmol/L and a two-hour glucose 
tolerance test value of 7.8 -11.1 mmol/L) 
s-related (use of ARVs could be past or current) : didanosine, stavudine or 
nevaripine (use of any duration);  efavirenz use > 16 mths (since about 60% of the 
cohort were efavirenz experienced, we only classified those exposed to efavirenz for 
longer than the median period (>16 mths) as at risk of hepatotoxicity) 
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TE was performed using Fibroscan (Echosens Fibroscan® 402 Touch). Steatosis was 
classified as mild (10%- <30%), moderate (30%-60%) or severe (>60%).  
Statistical analysis 
(%). Standard statistical tests were used: Mann-Whitney U, multivariable binary logistic 
regression. Statistical analyses were undertaken using SPSS Version 20.0 (Chicago, IL, 
USA). 
Results 
During the study period (2005-2012) 3872 HIV-positive individuals were identified.   
Since this was a retrospective study we were unable to determine why HIV physicians 
elected to investigate some and not other individuals with elevated ALT. Fig 1 shows 
how the final study cohort  (n=222) was selected. Table 1 shows data of the cohort at 
entry.  Of the 147 (66.2%) with CLD, 36 patients (24.5%) were considered to have 
clinically significant CLD. This included 11 (30.6%) with ≥F2 fibrosis of whom three 
had cirrhosis; 12 (33.3%) with moderate to severe steatosis, seven (22.2%) with both 
≥F2 fibrosis and moderate to severe steatosis and six (16.7%) with non-cirrhotic portal 
hypertension (NCPHT). Overall 6/36 (16.7%) with clinically significant liver disease 
developed hepatic decompensation 
Table 2a shows results of the univariate analysis in patients with and without CLD. 
Factors with p value <0.05 on univariate analysis were considered for entry into a 
multivariate binary logistic regression analysis. Due to collinearity between HIV 
duration and diagnosis pre-1996, BMI and weight, cholesterol and triglyceride, alcohol 
use/week at entry and alcohol use/week at last visit Receiver Operator Characteristic 
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(ROC) curves were performed to determine which variable had the best predictive value 
for CLD. Hence the following variables were finally entered into the multivariate binary 
regression analysis: age, HIV duration, BMI, triglyceride, fasting blood glucose, weekly 
alcohol intake at entry, PI-based therapy, use of didanosine, nevirapine and stavudine. 
Serum and triglyceride level (OR 1.482, 95% CI 1.053-2.086, p=0.024) was the only 
independent predictor of CLD (table 2b). 
The majority of patients (68.7%) with CLD had more than one risk factor the most 
common combination being potentially hepatotoxic ARV use and risk factors for the 
MS (31.3%). Overall one or more risk factor of the MS was seen in approximately two-
thirds of patients, potentially hepatotoxic ARV use in approximately three-quarters and 
alcohol use in 44% of patients.  
Discussion 
This retrospective cohort study has identified the significant yet under-recognised non- 
viral CLD burden in HIV monoinfected individuals with an elevated ALT. Despite a 
negative viral serology, about 30% (1047/3872) of our HIV cohort had a persistently 
elevated ALT over a six month period. Despite non-stringent CLD criteria, some degree 
of CLD was identified in two-thirds, this being clinically significant in approximately 
1:4 individuals. Potential risk factors or CLD included alcohol use (44.2%), one or more 
feature of the MS (68%) and ARV use (74.1%), with 68.7% having > 1 risk factor. 
Serum triglyceride (OR 1.482, 95% CI 1.053-2.086, p=0.024), was the only 
independent predictor of CLD. The most striking observation however was that only 
23% with persistently elevated ALT were investigated further with 58/1047 (5.5%) 
undergoing objective assessment of hepatic fibrosis and 45/1047 (4.3%) being referred 
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to Hepatology.  
The recently commissioned UK Liver report indicates that mortality from liver disease 
has increased 500% since 1970, this now constituting the third commonest cause of 
premature death in the UK. Alcohol causes about 75% of these deaths (Williams et al.; 
2014). Additionally with approximately about 25% of UK adults now defined as obese, 
about 1 in 20 are estimated to have non-alcoholic steatohepatitis (NASH)(Williams et 
al.; 2014). This is likely to be applicable to HIV positive individuals as well. Studies 
using CT scanning and ultrasound have in fact detected fatty liver in 13% and 37% of 
American and European HIV patients respectively (Crum-Cianflone et al.; 2009; Price 
et al.; 2014), consistent with our 47% prevalence. A recent American study reported that 
65% of HIV monoinfected individuals with elevated ALT had clinically significant liver 
pathology, including 55% with nonalcoholic steatohepatitis and 18% with bridging 
fibrosis, (Morse CG et al.; 2015)).  
Our prevalence of fatty liver was high  at 50% despite a young (mean age 47.6 +10.1 
yrs) Caucasian cohort with low MS risk factors (14.9% obese, 12.2% DM and 57.7% 
elevated triglyceride). Others have reported that HIV-positive individuals with NAFLD 
have a lower BMI (26.3 +0.5 vs. 30.2 +1.0, p= 001) and are more physically active 
(percentage of fat mass 19.4 +0.9 vs. 22.7 +1.2, p = 0.026) compared with their HIV-
negative counterparts with NAFLD (Mohammed et al.; 2007). Clearly additional factors 
contribute to NAFLD in HIV positive individuals particularly ARVs: stavudine and 
didanosine result in hepatic steatosis (McGovern B et al.; 2006); ritonavir elevates 
serum triglycerides and didanosine and lopinavir cause insulin resistance (Rao, Lee & 
Grunfeld, 2006).   
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Rates of ARLD have risen by almost 50% in the UK over the last seven years  (Sheron 
et al.; 2012) though only limited data exists on alcohol use and ARLD prevalence in 
HIV-positive individuals.  In our cohort ~40% were drinking alcohol above the national 
recommended levels with 18.9% being binge drinkers. Bonacini et al reported a 37% vs. 
25% all cause mortality (p=0.03) in those drinking < and > 50 gms alcohol/day, with 
lowest mortality rates in those consuming<10gms/day (Bonacini, 2011). “Safe” alcohol 
consumption is however difficult to define in the HIV monoinfected individuals who 
often have additional risk factors for CLD. In the current study of the 65 (44.2%) with 
CLD drinking in excess of recommended guidelines, all but 12 individuals potentially 
had additional risk factors for CLD. 
An important limitation of this study was that since < 25% with persistently elevated 
ALT were investigated, it is unclear if our results can be extrapolated to the whole 
cohort. Therefore, we are now prospectively screening the remainder (n=804) for CLD 
using TE with controlled attenuation parameter  - our initial results indicate a 47.5% and 
24.3% prevalence of hepatic steatosis and hepatic fibrosis (LSM >7.2kPa) consistent 
with our retrospective data. Additionally there are no significant differences in ALT and  
risk factors for chronic liver disease , between those investigated and those not initially 
investigated (data not shown) (Yishi T et al., 2015) 
In conclusion, this retrospective study demonstrates the significant yet under recognised 
non-viral liver CLD burden in HIV-positive individuals with an elevated ALT and 
underscores the need for HIV physicians in conjunction with their Hepatology 
colleagues to implement routine screening strategies and referral protocols. 
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Figure legends 
Fig1. Flow diagram showing how the study cohort was selected 
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Table 1. Demographic data at entry in whole cohort (n=222). 
Age (yrs) 47.6 ±10.1 
Males 208 (90.8 %) 
Ethnicity    White UK 
                   White non-UK 
                   Black non-UK 
                   Other 
143 (64.3%) 
43 (19.4%) 
27 (12.2%) 
9 (4.1%) 
HIV duration (yrs) 10.0 (6-17) 
CD4 at diagnosis (cells/mm3) 
CD4 nadir(cells/mm3) 
HIV Viral Load undetectable (<40mmol/L) 
325 (165 - 482) 
219 (106 - 350) 
202 (91.0%) 
HIV diagnosed pre-1996 37 (16.6%) 
Weight (kg) 
Body Mass Index (BMI) 
BMI >30 
77.7 ±15.5 
26.7 ±5.4 
33 (14.9%) 
Cholesterol (≤5mmol/L) 
HDL (≥1mmol/L) 
LDL (≤3mmol/L) 
Triglycerides (<2mmol/L) 
Chol:HDL (≤4mmol/L) 
5.4 ±1.2 
1.2 ±0.4 
3.0 ±1.0 
2.9 ±2.7 
4.5 ±2.7 
Fasting blood glucose  (4-5.9 mmol/L) 5.6 ±1.7 
Diabetes Mellitus  27 (12.2%) 
Lipodystrophy 34 (14.8%) 
Alcohol intake (units) 
Alcohol (units/wk) at entry 
Alcohol (units/wk) at last visit 
Alcohol (units/day) 
Binge drinking 
Drinking >  recommended weekly limit 
 
 
20 (2-38) 
7 (0-21) 
0 (0-7) 
42 (18.9%) 
83 (37.4%) 
 
ARV history 
ARV duration (mths) 
NNRTI-based therapy 
PI-based therapy 
Didanosine  
Nevirapine  
Efavirenz  
Ritonavir  
Darunavir  
Stavudine  
Saquinavir  
 
72 (0-390) 
167 (75.2%) 
128 (57.7%) 
60 (27%) 
47 (21.2%) 
139 (62.6%) 
113 (50.9%) 
46 (20.7%) 
45 (20.3%) 
15 (6.8%) 
Initial ALT(<40 iu/L) 
Highest ALT 
Most recent ALT 
54 (46-70) 
90 (64-125) 
35 (25-50) 
Further investigations 
Ultrasound 
CT Scan 
MRI 
Transient elastography 
Liver biopsy 
 
198 (89.2%) 
43 (19.4%) 
8 (3.6%) 
16 (7.2%) 
42 (18.9%) 
Radiological findings 
  Fatty liver 
  Heterogeneous/ irregular liver 
  Varices/ abnormal portal venous flow 
 
105 (47.3%) 
21 (9.5%) 
11 (5.0%) 
12 
 
  Ascites 
Liver Biopsy (n=42) 
  Steatosis :   None   
                     Mild 
                     Moderate 
                     Severe 
  Fibrosis     F0 
                    F1 
                    F2 
                    F3-F4 
Transient Elastography (n=16) 
 F0 
 F1 
 F2 
 F3-4 
2 (0.9%) 
 
18 (42.9%) 
5 (11.9%) 
13 (31.0%) 
6 (14.3%) 
14 (33.3%) 
16 (38.1%) 
4 (9.5%) 
9 (21.4%) 
 
8 (50%) 
3 (21.4%) 
3 (21.4%) 
2 (14.3%) 
Chronic liver disease (CLD) 
Clinically significant CLD 
Non-CLD 
147 (66.2%) 
36/147 (24.5%) 
75 (33.8%) 
Referred to Hepatology  45 (20.3%) 
Some patients fulfilled more than one criteria for CLD 
DM diabetes mellitus,  HDL  High density lipoprotein, LDL  Low density lipoprotein, CT 
computerised tomography, MRI magnetic resonance imaging, ARV  antiretrovirals, NNRTI non-
nucleoside reverse transcriptase inhibitors 
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Table 2a. Univariate analysis of factors associated with chronic liver disease  
Parameter Chronic Liver 
Disease  
n=147 (60.2%) 
No Chronic 
Liver Disease  
n=75 (30.7%) 
OR  95% CI P value 
Age (yrs) 49.03 ±9.69 44.08 ±9.80 1.062 1.029-1.097 <0.001 
Males  140 (95.2%) 68 (90.7%) 0.486 0.164-1.440 0.193 
Ethnicity   
White UK 
White non-UK 
Black non-UK 
 Other 
 
93 (63.3%) 
32 (21.8%) 
15 (10.2%) 
6 (4.1%) 
 
49 (65.3%) 
11 (14.7%) 
12  (16%) 
3    (4%) 
 
0.949 
  
0.751 
Duration of HIV (years) 12.8 ±8.2 8.2 ±4.7 1.137 1.079-1.199 <0.001 
CD4 at diagnosis 290.0 (120-494) 283.0 (175-409) 1.000 0.999-1.002 0.513 
CD4 nadir 217 (84-319) 284 (151- 372) 0.999 0.997-1.000 0.112 
No. diagnosed pre-1996 36 (97.3%) 1 (2.7%) 24.00 3.220-178.878 0.002 
Body mass index (BMI) 
Weight 
26.8 ±4.6 
78.2 ±14.4 
25.4 ±4.4 
73.4 ±12.2 
1.080 
1.022 
1.002-1.164 
1.001-1.043 
0.043 
0.039 
Cholesterol (mmol/L) 
HDL (mmol/L) 
LDL (mmol/L) 
Triglycerides(mmol/L) 
Chol:HDL (mmol/L) 
FBG (mmol/L) 
5.5 ±1.3 
1.3 ±0.5 
2.9 ±1.1 
2.5 (5-15.5) 
4.5 ±1.7 
5.8 ±2.0 
5.2 ±1.0 
1.2 ±0.4 
3.1 ± 0.9 
1.80 (5-9) 
4.6 ±1.6  
5.2 ±0.2 
1.284 
1.612 
0.897 
1.238 
0.963 
1.359 
1.011-1.632 
0.837-3.103 
0.682-1.181 
1.042-1.470 
0.815-1.138 
1.048-1.761 
0.040 
0.153 
0.441 
0.015 
0.668 
0.021 
Alcohol  (units/wk) at  
entry 
Alcohol(units/wk) at last 
follow up 
Alcohol (daily units) 
Binge drinking 
21.0 (1.3-57.5) 
 
10.0 (0- 24.8) 
 
2.0 (0-9) 
32 (21.8%) 
10.0 (2-30) 
 
0 (0-18.8)  
 
0 (0-5) 
10 (13.2%) 
1.011 
 
1.023 
 
1.060 
1.739 
1.002-1.021 
 
1.003-1.043 
 
0.999-1.125 
0.790-3.829 
0.024 
 
0.024 
 
0.055 
0.169 
HAART  
Duration HAART(mths) 
93 (63.7%) 
99 (50-150) 
37 (48.7%) 
60 (40-96) 
 
1.013 
0.090-0.101 
1.007-1.019 
0.098 
<0.001 
NNRTI-based therapy 
Duration NNRTI 
109 (74.7%) 
48 (24-106.5) 
58 (76.3%) 
48 (24-72) 
0.841 
1.007 
0.437-1.618 
0.989-1.187 
0.604 
0.084 
PI-based therapy 
Duration PI-based  
91 (62.0%) 
48 (36-96) 
37 (48.7%) 
48 (24-67.5) 
1.727 
1.008 
0.081-0.091 
-3.788-28.401 
0.049 
0.094 
Didanosine 
Duration Didanosine 
52 (35.6%) 
48 (19.5-86.0) 
8 (10.5%) 
36 (12-36) 
4.893 
1.022 
2.179-10.989 
0.993-1.022 
<0.001 
0.140 
14 
 
Nevirapine 
Duration Nevirapine 
37 (25.3%) 
60 (24-114) 
10 (13.2%) 
12 (6-12) 
2.312 
1.002 
1.077-4.966 
0.989-1.015 
0.032 
0.739 
Efavirenz 
Duration Efavirenz 
88 (60.3%) 
36 (12-72) 
51 (67.1%) 
36 (12-54) 
0.781 
1.005 
0.432-1.414 
0.996-1.014 
0.415 
0.298 
Ritonavir 
Duration Ritonavir 
76 (52.1%) 
36 (12-48) 
36 (47.4%) 
24 (12-48) 
1.324 
1.086 
0.755-2.323 
0.945-1.247 
0.328 
0.244 
Darunavir 
Duration Darunavir 
25 (17.1%) 
48 (21-60) 
19 (25%) 
36 (21-48) 
0.686 
1.191 
0.352-1.338 
0.854-1.661 
0.269 
0.303 
Stavudine 
Duration Stavudine 
40 (27.4%)   
36 (12-48) 
5 (6.7%) 
60 (35.5-90) 
5.545 
0.965 
2.084-14.749 
0.930-1.001 
<0.001 
0.058 
Saquinavir 
Duration Saquinavir 
11 (7.5%) 
36 (24-82) 
4 (5.3%) 
36 (6-87) 
1.502 
1.004 
0.461-4.890 
0.966-1.044 
0.499 
0.830 
Further investigations 
USS 
CT 
MRI 
Fibroscan 
Biopsy 
 
136 (92.5%) 
21 (14.3%) 
5 (3.4%) 
16 (11.0%) 
39 (92.9%) 
 
60 (82.2%) 
22 (30.1%) 
0 (4.3%) 
0 
3 (7.1%) 
 
2.592 
0.402 
1.168 
 
8.667 
 
1.100-6.110 
0.204-0.791 
0.270-5.054 
0.003-0.006 
2.580-29.109 
 
0.029 
0.008 
0.835 
0.003 
<0.001 
Referred to hepatology 40 (27.4%) 5 (6.6%) 5.234 1.970-13.907 <0.001 
BMI = body mass index, total cholesterol (normal ≤5mmol/L), HDL = high density lipoprotein 
(normal ≥1mmol/L), LDL = low density lipoprotein (normal ≤3mmol/L), Triglycerides (normal 
<1.69mmol/L), Chol:HDL ratio (normal ≤4mmol/L), FBG = fasting blood glucose (normal 
<6.1mmol/L, impaired fasting glucose 6.1-6.9mmol/L) 
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Table 2b.  Multivariate analysis of factors associated with chronic liver disease 
 P value Exp (B) 95% CI for Exp (B) 
Age 0.254 1.030 0.979 1.084 
Duration of HIV 0.117 1.082 0.980 1.195 
BMI 0.056 1.105 0.997 1.224 
PI based therapy 0.809 1.115 0.460 2.703 
Didanosine therapy 0.797 1.221 0.266 5.599 
Nevirapine therapy 0.497 0.658 0.196 2.205 
Stavudine therapy 0.157 3.290 0.632 17.126 
Triglyceride 0.024 1.482 1.053 2.086 
Fasting blood glucose 0.866 1.034 0.700 1.528 
Weekly intake alcohol 0.101 1.017 0.997 1.037 
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Fig 1. Flow diagram showing how the study cohort was selected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elevated ALT >1ULN on two occasions over 
six months 
n = 1654 (42.7%) 
Elevated ALT >1ULN on two occasions 6 
months apart 
       n = 1047 (27.0%) 
 
Excluded as elevated 
ALT < 6 months apart 
       n = 247 (6.3%) 
Further radiological or histological 
investigation n = 243 (23.2%) 
No further 
investigation 
n = 804 (76.8%)  
 
Total HIV cohort (2005-2012) 
n = 3872  
Excluded as 
current/historic 
HBV/HCV infection 
      n = 360 (6.4%) 
Chronic liver disease 
n = 147 (66.2%)           
No chronic liver 
disease 
n = 75 (33.8%)          
Excluded n=23                                      
(medical records unavailable n=17, HIV 
related causes for raised ALT n=5 
Final study cohort 
         n=222 
